2026 Volume 68 Issue 4 Pages 198-204
Purpose: To investigate the prognostic significance of preoperative serum solute carrier family 7 member 11 (SLC7A11) in patients with stage I-III oral squamous cell carcinoma (OSCC).
Methods: This prospective observational study consecutively enrolled 195 patients with stage I-III OSCC. Preoperative serum SLC7A11 levels were measured using enzyme-linked immunosorbent assay, and then patients were followed for 24 months. Data on disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics were collected.
Results: Recurrence and/or death occurred in 54 patients (27.7%). The preoperative serum SLC7A11 level was significantly higher in patients with a poor outcome (P < 0.05). ROC analysis demonstrated that serum SLC7A11 had good discriminatory performance for poor outcome, with an AUC of 0.765. Multivariate Cox regression analysis showed that an elevated preoperative serum SLC7A11 level remained independently associated with both DFS (hazard ratio [HR] = 1.416 per 10 ng/L increase, 95% confidence interval [CI] 1.196-1.675, P < 0.001) and OS (HR = 1.340 per 10 ng/L increase, 95% CI 1.065-1.687, P = 0.013).
Conclusion: An elevated preoperative serum SLC7A11 level is associated with unfavorable prognosis in patients with stage I-III OSCC undergoing curative surgery. However, further independent validation is required before serum SLC7A11 can be considered for clinical risk stratification or individualized follow-up planning.